Eupraxia Cash Per Share vs Free Cash Flow Yield Analysis

EPRX Stock

CAD 7.32 0.14 1.88%

Eupraxia Pharmaceuticals financial indicator trend analysis is much more than just examining Eupraxia Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eupraxia Pharmaceuticals is a good investment. Please check the relationship between Eupraxia Pharmaceuticals Cash Per Share and its Free Cash Flow Yield accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eupraxia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Cash Per Share vs Free Cash Flow Yield

Cash Per Share vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eupraxia Pharmaceuticals Cash Per Share account and Free Cash Flow Yield. At this time, the significance of the direction appears to have pay attention.

The correlation between Eupraxia Pharmaceuticals' Cash Per Share and Free Cash Flow Yield is -0.91. Overlapping area represents the amount of variation of Cash Per Share that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of Eupraxia Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eupraxia Pharmaceuticals' Cash Per Share and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash Per Share of Eupraxia Pharmaceuticals are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Cash Per Share i.e., Eupraxia Pharmaceuticals' Cash Per Share and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

-0.91

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Cash Per Share

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from Eupraxia Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eupraxia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eupraxia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

As of the 2nd of August 2025, Issuance Of Capital Stock is likely to grow to about 57.3 M, while Selling General Administrative is likely to drop about 6.6 M.

	2022	2023	2024	2025 (projected)
Depreciation And Amortization	193.3K	209.9K	241.4K	164.2K
Interest Income	673.2K	863.0K	1.2M	714.5K

Depreciation And Amortization Interest Income

Eupraxia Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Short Term Debt	Common Stock
Total Assets		0.5	0.47	-0.01	0.69	0.7	0.54	-0.75	-0.84	0.91	0.67	0.94	-0.85	0.8	0.56	0.55	0.93	0.18	0.74	0.11	0.16	0.62	1.0	0.75	-0.14	0.95
Short Long Term Debt Total	0.5		0.74	0.7	-0.03	-0.21	0.45	0.13	-0.76	0.52	0.52	0.51	-0.72	0.56	0.22	0.25	0.73	0.82	0.82	0.24	0.74	-0.12	0.49	0.01	0.69	0.6
Other Current Liab	0.47	0.74		0.55	0.21	-0.04	0.29	-0.06	-0.83	0.64	0.39	0.58	-0.61	0.7	-0.12	-0.12	0.69	0.34	0.71	0.11	0.45	-0.32	0.47	0.16	0.39	0.62
Total Current Liabilities	-0.01	0.7	0.55		-0.61	-0.59	0.24	0.48	-0.37	-0.02	0.21	-0.04	-0.23	0.12	-0.12	-0.09	0.28	0.54	0.45	0.59	0.93	-0.37	-0.01	-0.6	0.95	0.22
Total Stockholder Equity	0.69	-0.03	0.21	-0.61		0.89	0.21	-0.84	-0.49	0.79	0.33	0.79	-0.52	0.59	0.24	0.22	0.49	-0.22	0.28	-0.4	-0.54	0.49	0.7	0.98	-0.68	0.56
Net Tangible Assets	0.7	-0.21	-0.04	-0.59	0.89		0.29	-0.97	-0.39	0.68	0.37	0.71	-0.45	0.43	0.38	0.34	0.44	-0.37	0.16	-0.11	-0.46	0.77	0.7	0.9	-0.68	0.58
Property Plant And Equipment Net	0.54	0.45	0.29	0.24	0.21	0.29		-0.4	-0.56	0.54	0.98	0.56	-0.51	0.24	0.62	0.63	0.6	0.47	0.28	0.44	0.45	0.5	0.54	0.31	0.15	0.56
Net Debt	-0.75	0.13	-0.06	0.48	-0.84	-0.97	-0.4		0.49	-0.74	-0.46	-0.74	0.53	-0.51	-0.45	-0.41	-0.55	0.37	-0.27	-0.08	0.32	-0.77	-0.75	-0.86	0.62	-0.68
Retained Earnings	-0.84	-0.76	-0.83	-0.37	-0.49	-0.39	-0.56	0.49		-0.92	-0.67	-0.89	0.92	-0.84	-0.28	-0.28	-0.95	-0.36	-0.87	-0.27	-0.42	-0.22	-0.84	-0.5	-0.22	-0.93
Cash	0.91	0.52	0.64	-0.02	0.79	0.68	0.54	-0.74	-0.92		0.66	0.99	-0.89	0.82	0.38	0.36	0.89	0.18	0.73	0.05	0.07	0.43	0.91	0.8	-0.15	0.91
Non Current Assets Total	0.67	0.52	0.39	0.21	0.33	0.37	0.98	-0.46	-0.67	0.66		0.68	-0.6	0.4	0.63	0.63	0.72	0.48	0.39	0.35	0.41	0.51	0.67	0.42	0.12	0.68
Cash And Short Term Investments	0.94	0.51	0.58	-0.04	0.79	0.71	0.56	-0.74	-0.89	0.99	0.68		-0.89	0.76	0.47	0.46	0.89	0.23	0.72	0.0	0.09	0.52	0.94	0.82	-0.17	0.91
Net Receivables	-0.85	-0.72	-0.61	-0.23	-0.52	-0.45	-0.51	0.53	0.92	-0.89	-0.6	-0.89		-0.72	-0.51	-0.51	-0.92	-0.43	-0.91	-0.24	-0.37	-0.41	-0.85	-0.58	-0.14	-0.89
Common Stock Shares Outstanding	0.8	0.56	0.7	0.12	0.59	0.43	0.24	-0.51	-0.84	0.82	0.4	0.76	-0.72		0.06	0.05	0.84	0.06	0.76	0.06	0.09	0.1	0.8	0.55	0.0	0.86
Long Term Debt Total	0.56	0.22	-0.12	-0.12	0.24	0.38	0.62	-0.45	-0.28	0.38	0.63	0.47	-0.51	0.06		1.0	0.5	0.36	0.33	0.22	0.25	0.79	0.56	0.43	-0.17	0.43
Non Current Liabilities Total	0.55	0.25	-0.12	-0.09	0.22	0.34	0.63	-0.41	-0.28	0.36	0.63	0.46	-0.51	0.05	1.0		0.5	0.4	0.34	0.22	0.28	0.77	0.55	0.41	-0.13	0.42
Capital Surpluse	0.93	0.73	0.69	0.28	0.49	0.44	0.6	-0.55	-0.95	0.89	0.72	0.89	-0.92	0.84	0.5	0.5		0.37	0.88	0.29	0.42	0.39	0.93	0.55	0.13	0.97
Capital Lease Obligations	0.18	0.82	0.34	0.54	-0.22	-0.37	0.47	0.37	-0.36	0.18	0.48	0.23	-0.43	0.06	0.36	0.4	0.37		0.45	0.06	0.66	-0.06	0.18	-0.13	0.65	0.19
Other Current Assets	0.74	0.82	0.71	0.45	0.28	0.16	0.28	-0.27	-0.87	0.73	0.39	0.72	-0.91	0.76	0.33	0.34	0.88	0.45		0.26	0.53	0.15	0.74	0.32	0.35	0.82
Other Stockholder Equity	0.11	0.24	0.11	0.59	-0.4	-0.11	0.44	-0.08	-0.27	0.05	0.35	0.0	-0.24	0.06	0.22	0.22	0.29	0.06	0.26		0.66	0.19	0.11	-0.34	0.48	0.32
Total Liab	0.16	0.74	0.45	0.93	-0.54	-0.46	0.45	0.32	-0.42	0.07	0.41	0.09	-0.37	0.09	0.25	0.28	0.42	0.66	0.53	0.66		-0.07	0.16	-0.46	0.87	0.33
Net Invested Capital	0.62	-0.12	-0.32	-0.37	0.49	0.77	0.5	-0.77	-0.22	0.43	0.51	0.52	-0.41	0.1	0.79	0.77	0.39	-0.06	0.15	0.19	-0.07		0.62	0.62	-0.42	0.48
Total Current Assets	1.0	0.49	0.47	-0.01	0.7	0.7	0.54	-0.75	-0.84	0.91	0.67	0.94	-0.85	0.8	0.56	0.55	0.93	0.18	0.74	0.11	0.16	0.62		0.75	-0.14	0.95
Net Working Capital	0.75	0.01	0.16	-0.6	0.98	0.9	0.31	-0.86	-0.5	0.8	0.42	0.82	-0.58	0.55	0.43	0.41	0.55	-0.13	0.32	-0.34	-0.46	0.62	0.75		-0.68	0.6
Short Term Debt	-0.14	0.69	0.39	0.95	-0.68	-0.68	0.15	0.62	-0.22	-0.15	0.12	-0.17	-0.14	0.0	-0.17	-0.13	0.13	0.65	0.35	0.48	0.87	-0.42	-0.14	-0.68		0.06
Common Stock	0.95	0.6	0.62	0.22	0.56	0.58	0.56	-0.68	-0.93	0.91	0.68	0.91	-0.89	0.86	0.43	0.42	0.97	0.19	0.82	0.32	0.33	0.48	0.95	0.6	0.06

Click cells to compare fundamentals

Eupraxia Pharmaceuticals Account Relationship Matchups

Eupraxia Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.5M	31.2M	25.9M	26.7M	34.9M	18.2M
Short Long Term Debt Total	17.8M	9.6M	10.5M	13.8M	15.8M	11.4M
Other Current Liab	6.9M	2.1M	4.0M	11.8M	13.5M	14.2M
Total Current Liabilities	22.5M	2.3M	4.1M	25.5M	3.1M	2.9M
Total Stockholder Equity	(21.2M)	20.4M	12.9M	2.9M	33.4M	35.1M
Net Tangible Assets	(17.7M)	(21.2M)	20.4M	12.9M	14.8M	15.5M
Property Plant And Equipment Net	315.3K	589.1K	695.5K	601.6K	424.9K	567.5K
Net Debt	12.4M	(11.3M)	(14.2M)	(11.7M)	(10.5M)	(10.0M)
Retained Earnings	(51.2M)	(74.2M)	(97.4M)	(139.1M)	(131.0M)	(124.5M)
Cash	150.1K	20.9M	24.7M	25.5M	33.1M	34.8M
Non Current Assets Total	315.3K	620.4K	698.8K	610.7K	505.7K	584.7K
Cash And Short Term Investments	150.1K	29.9M	24.7M	25.5M	33.1M	34.8M
Net Receivables	620.6K	429.7K	121.5K	251.3K	226.2K	214.9K
Liabilities And Stockholders Equity	1.5M	31.2M	25.9M	26.7M	34.9M	18.2M
Capital Surpluse	6.2M	13.9M	18.0M	17.5M	20.5M	12.4M
Capital Lease Obligations	251.2K	197.6K	137.8K	53.3K	71.9K	142.8K
Other Current Assets	367.5K	271.0K	319.5K	357.0K	410.5K	273.0K
Other Stockholder Equity	6.2M	(2.7M)	18.0M	23.1M	(4.2M)	(4.0M)
Total Liab	23.1M	11.7M	14.5M	25.5M	1.5M	1.5M
Net Invested Capital	(8.7M)	29.7M	23.3M	12.6M	1.7M	1.6M
Total Current Assets	1.1M	30.6M	25.2M	26.1M	34.4M	17.6M
Net Working Capital	(21.4M)	28.3M	21.0M	429.2K	31.3M	32.9M
Short Term Debt	16.6M	17.6M	154.8K	175.8K	13.8M	0.0
Common Stock	23.8M	80.7M	92.3M	122.5M	116.4M	69.6M
Property Plant Equipment	315.3K	589.1K	695.5K	456.3K	424.9K	547.5K
Short Long Term Debt	12.5M	94.9K	107.6K	10.4M	9.4M	5.1M
Capital Stock	23.8M	80.7M	92.3M	92.9M	148.1M	76.2M
Property Plant And Equipment Gross	699.1K	903.6K	1.1M	854.3K	884.6K	736.4K

Pair Trading with Eupraxia Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eupraxia Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Eupraxia Stock

0.88	JPM	JPMorgan Chase	Pair Corr
0.79	BOFA	Bank of America	Pair Corr
0.88	CITI	CITIGROUP CDR	Pair Corr
0.75	RY	Royal Bank	Pair Corr
0.84	TD	Toronto Dominion Bank	Pair Corr

Moving against Eupraxia Stock

0.46

DFN-PA

Dividend 15 Split

Pair Corr

The ability to find closely correlated positions to Eupraxia Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eupraxia Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eupraxia Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eupraxia Pharmaceuticals to buy it.

The correlation of Eupraxia Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eupraxia Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eupraxia Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Eupraxia Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Eupraxia Stock

Balance Sheet is a snapshot of the financial position of Eupraxia Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Eupraxia Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Eupraxia Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Eupraxia currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Eupraxia Cash Per Share vs Free Cash Flow Yield Analysis

Cash Per Share vs Free Cash Flow Yield

Cash Per Share vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Cash Per Share

Free Cash Flow Yield

Eupraxia Pharmaceuticals fundamental ratios Correlations

Eupraxia Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Eupraxia Pharmaceuticals fundamental ratios Accounts

Pair Trading with Eupraxia Pharmaceuticals

Moving together with Eupraxia Stock

Moving against Eupraxia Stock

Other Information on Investing in Eupraxia Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Liabilities Total	+ 1.0	Long Term Debt Total
Cash And Short Term Investments	+ 0.99	Cash
Net Working Capital	+ 0.98	Total Stockholder Equity
Non Current Assets Total	+ 0.98	Property Plant And Equipment Net
Common Stock	+ 0.97	Capital Surpluse

Net Debt	- 0.97	Net Tangible Assets
Capital Surpluse	- 0.95	Retained Earnings
Common Stock	- 0.93	Retained Earnings
Capital Surpluse	- 0.92	Net Receivables
Cash	- 0.92	Retained Earnings
Other Current Assets	- 0.91	Net Receivables